Chongqing Pharmaceutical Research Institute Co., Ltd.

Chongqing Pharmaceutical Research Institute (CPRI) is a comprehensive scientific research institution and industrialization base jointly established by Shanghai Fosun Pharmaceutical and Chongqing Pharmaceutical Group, mainly engaged in the research and development of chemically synthesized drugs and Chinese and Western drug formulations. It has a strong R&D management team composed of national new drug review experts, overseas scientists, and senior engineers. The company has established a new drug R&D system with a complete set of disciplines, possesses excellent scientific research facilities, advanced testing and experimental instruments, and adequate pilot-scale testing equipment.
Over the past two decades, it has completed more than 200 national key projects under the "Seventh Five-Year Plan", "Eighth Five-Year Plan", "Eleventh Five-Year Plan", and "Twelfth Five-Year Plan", "863 Program" projects, as well as Chongqing key research projects and science and technology plan projects, and has won more than 30 national and provincial/ministerial-level science and technology achievement awards. It has cumulatively applied for more than 200 invention patents, including 20 PCT patents and 27 foreign patents, and has obtained 70 Chinese patent authorizations and 14 foreign patent authorizations. More than 80% of its research achievements have been transformed into productivity, cumulatively generating an industrial output value exceeding 6 billion yuan. It has been recognized as a *** high-tech enterprise, *** enterprise technology center (affiliated with Fosun Pharmaceutical), Chongqing innovative enterprise, and Chongqing Chemical Pharmaceutical Engineering Technology Research Center.
Facing future opportunities and challenges, the company will adhere to the corporate spirit of "Cooperation, Passion, Responsibility, Innovation", persist in taking the creation of new drugs with independent intellectual property rights as its main line, and implement talent strategy, innovation strategy, and internationalization strategy. By building distinctive technology platforms for new drug R&D, it will establish a new drug research and development system and industrialization pilot implementation system that emphasizes both generic innovation, is standardized, has outstanding professional characteristics, and is recognized by mainstream international markets, and build a high-tech enterprise that is first-class in China, aligned with international standards, and driven by pharmaceutical technology R&D.
The company is located in Chongqing CBD (Nan'an District), with convenient transportation and living conditions. It now sincerely invites pharmaceutical-related talents to join, and the company will provide good remuneration, benefits, and training and development opportunities, and work hand in hand with you to create a more brilliant tomorrow for CPRI!

Contact: ************** ***********
Resume submission: ①E-mail: hr@*; ② Submit via 51job, Liepin, Zhaopin, and Lianying Online.